Corporate
NIVELLES, Belgium – April 14, 2025 Quantoom Biosciences, a full-stack RNA partner for mRNA- and saRNA-based vaccines and therapeutics, is…
Manchester, CT, USA & NIVELLES, Belgium – March 31, 2025 Quantoom Biosciences and DIANT Pharma Inc. are proud to announce…
Pirbright, UK & Nivelles, Belgium – Thursday, March 13, 2025 The Centre for Veterinary Vaccine Innovation and Manufacturing (CVIM), part…
Wednesday, March 5, 2025 TechInvention Lifecare Pvt. Ltd. (TechInvention) is proud to announce a strategic collaboration with Belgium-based Quantoom Biosciences…
Cairo, Egypt – February 5, 2025 – Africa’s EVA Pharma, France’s DNA Script, and Belgium’s Quantoom Biosciences have signed a…
Rio de Janeiro, Brazil – November 29, 2024 – During the Belgian Economic Mission to Brazil, a historic Memorandum of…
ST Pharm, a leading technology-driven RNA CDMO, and Quantoom Biosciences (also referred as “Quantoom”), a specialized RNA technology platform developer,…
DURHAM, North Carolina – Quantoom Biosciences S.A. (“Quantoom”), part of Univercells S.A., focused on mRNA production technologies for vaccines and…
Quantoom Biosciences S.A. (“Quantoom”), part of Univercells S.A. is proud to announce its significant collaboration with the Institute of Technology…
The Ntensify™ Midi System Sets the Stage for Equitable Vaccine Access Quantoom Biosciences S.A. (“Quantoom”), a Univercells company, proudly announces…
Quantoom Biosciences (‘Quantoom’) is thrilled to announce a new collaboration with Stevanato Group, a leading global provider of drug containment and…
Univercells S.A. (Univercells) today announced its acquisition of SynHelix, a biotechnology company that aims to debottleneck biotherapeutics development through an unprecedented…
Quantoom Biosciences S.A. (“Quantoom”), a biotech with the mission to improve access to essential medicines and autonomy in bioproduction through…
Univercells S.A. introduces its latest affiliate, Quantoom Biosciences S.A., a biotech with the mission to improve access to essential medicines…